Soligenix Inc
NASDAQ:SNGX
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.3999
  • TODAY'S CHANGE (%)
    0.0169 (4.4125%)
  • Bid / Lots
    0.3925/ 2
  • Ask / Lots
    0.3999/ 40
  • Open / Previous Close
    0.3764 / 0.3830
  • Day Range
    0.3764
    0.4000
  • 52 Week Range
    0.3705
    4.2000
  • Volume
    267,417

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 4 hours ago by PR Newswire
      Companies Mentioned: SNGX

      -- Includes thermostabilized Ebola vaccines MarVax™ and SuVax™

      -- Includes nanoemulsion adjuvant compatible with lyophilization

      Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received notice of intent to grant additional patents based on its patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines" in the United Kingdom and South Africa, with other international jurisdictions pending. The Company has previously announced multiple issued patents within the same patent family in the United States (U.S.). The allowed claims are directed to unique, proprietary compositions and methods related to combinations of glycoprotein antigens with nanoemulsion adjuvants comprising sucrose fatty acid esters prior to lyophilization. The described vaccine platform has previously been successfully applied to mono-, bi- and tri-valent candidates for Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus, including monovalent vaccines SuVax™ (targeting Sudan ebolavirus) and MarVax™ (targeting Marburg marburgvirus).

    • 4 hours ago by Dow Jones
      Companies Mentioned: SNGX

      Disease were also recorded in Ghana in 2022 and 2021.

      Transmission of filoviruses requires direct contact with bodily fluids from an infected person or contact with infected animals. The mortality rates following filovirus infections are extremely high, and, in the absence of wide availability of effective therapeutics, are affected by the quality of supportive care available with a focus on early initiation of treatment. Resolution of the disease largely depends on the patient's own immune system. There are limited treatment options for Ebola Virus Disease and no available treatments for Sudan Virus or Marburg Virus Disease, although steady progress has also been made in development of immunotherapeutics for filoviruses beyond Zaire ebolavirus. There are approved vaccines for Ebola virus (Zaire ebolavirus), requiring stringent ultra-low cold-chain storage, but no efficacious vaccines are yet available for Marburg virus (Marburg marburgvirus) or Sudan virus (Sudan ebolavirus).

  • Apr 18, 2024

      Show headlines and story abstract

    • 8:32AM ET on Thursday Apr 18, 2024 by Dow Jones
      Companies Mentioned: SNGX

    • 8:30AM ET on Thursday Apr 18, 2024 by PR Newswire
      Companies Mentioned: SNGX

      Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 11,875,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $0.40 per share, will be exercisable immediately and will expire five years from the issuance date.

    • 8:30AM ET on Thursday Apr 18, 2024 by Dow Jones
      Companies Mentioned: SNGX

      Soligenix Announces Pricing of $4.75 Million Public Offering

      PR Newswire

      PRINCETON, N.J., April 18, 2024

      PRINCETON, N.J., April 18, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 11,875,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $0.40 per share, will be exercisable immediately and will expire five years from the issuance date.

Peers Headlines